{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-310595","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.989421+00:00","generated_at":"2026-05-16T13:58:43.147109+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Wave Life Sciences reports positive Phase 1 INLIGHT data: WVE-007 reduces visceral fat 9.4%, preserves lean mass","bullets":["Single 240 mg WVE-007 dose: 9.4% visceral fat loss (p=0.02), 4.5% total fat reduction, 3.2% lean mass gain at 3 months.","Serum Activin E suppressed up to 78%; durable reductions support once or twice-yearly dosing.","No severe TEAEs, no discontinuations, no clinically meaningful changes in lipids or liver function.","Phase 2 planning for monotherapy, add-on to incretins, and maintenance post-incretin therapy.","Next data: Q1 2026 6-month follow-up from 240 mg cohort and 3-month from 400 mg cohort."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-310595","json":"https://secwatch.observer/filing/0001193125-25-310595.json","markdown":"https://secwatch.observer/filing/0001193125-25-310595.md","text":"https://secwatch.observer/filing/0001193125-25-310595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312525310595/0001193125-25-310595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312525310595/d20484d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:58:43.147109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}